According to the Center for Health Care Strategies, nine out of 10 adults struggle with health literacy in the United States.
Published literature has shown the level of a patient’s personal health literacy — defined by the CDC as “the degree to which individuals have the ability to find, understand, and use information and services to inform health-related decisions and actions for themselves and others” — may impact patient-reported outcomes, with limited health literacy associated with poor results.
In an editorial published in The Journal of Bone and Joint Surgery in 2024, Zachary C. Lum,

COPENHAGEN, Denmark — In this Healio video, Balazs Halmos, MD, MS, director of thoracic oncology and clinical cancer genomics at Montefiore Einstein Cancer Center, discusses results of the Beamion LUNG-1 trial.
The phase 1b study evaluated the safety and efficacy of 120 mg zongertinib (Hernexeos, Boehringer Ingelheim) for treatment-naive patients with advanced non-small cell lung cancer with a HER2 mutation in the tyrosine kinase domain. The results were presented at European Lung Cancer Congress.
“For treatment naive patients, zongertinib is exceedingly effective,” Halmos said.

Once-daily orforglipron induced greater reductions in body weight than placebo at 72 weeks among adults aged at least 65 years with obesity, according to data presented at the European Congress on Obesity.
As Healio previously reported, orforglipron (Foundayo, Eli Lilly) conferred larger decreases in body weight than placebo among adults with obesity, both in those without diabetes in the ATTAIN-1 trial and among those with type 2 diabetes in the ATTAIN-2 trial. In April, the FDA approved orforglipron for the treatment of overweight or obesity in adults.
In a new analysis of the ATTAIN-1 and

Sacubitril/valsartan improved exercise hemodynamics, oxygen uptake and symptom burden in patients with heart failure with preserved ejection fraction and atrial functional mitral regurgitation, researchers reported.
Sacubitril/valsartan (Entresto, Novartis) was also associated with improvement in N-terminal pro-B-type natriuretic peptide and structural changes in patients with HFpEF and at least moderate mitral regurgitation, according to data presented at Heart Failure 2026 and simultaneously published in Circulation.
“Secondary or functional mitral regurgitation identifies a high-risk

A monoclonal antibody delivered through IV infusion did not confer greater reductions in hypoglycemic events compared with placebo for children with congenital hyperinsulinism at 24 weeks, according to data from a phase 3 trial.
Ersodetug (Rezolute) is an investigational insulin receptor modulating monoclonal antibody under the development for the treatment of congenital hyperinsulinism, a condition that leads to severe hypoglycemia in newborns and infants. According to data presented at the Pediatric Endocrine Society Annual Meeting, ersodetug reduced hypoglycemia by up to 75% in an

Approximately a third of patients with pancreatic ductal adenocarcinoma do not have elevated or detectable levels of a biomarker commonly used to measure response to therapy.
An AI tumor marker derived from routinely collected data could provide prognostic information on treatment completion and survival similar to that seen in patients who have measurable cancer antigen 19-9 (CA19-9).
“This behaves just like CA19-9 does clinically,” Anai N. Kothari, MD, MS, assistant professor of surgical oncology at Medical College of Wisconsin, told Healio. “It tracks response, predicts outcomes and can help

DENVER — In this video, Melinda J. Gooderham, MD, MSc, FRCPC, FAAD, discusses the new oral therapies available to treat plaque psoriasis that were presented at the American Academy of Dermatology Annual Meeting.
Gooderham discussed three new oral therapies for plaque psoriasis — two tyrosine kinase 2 inhibitors with similar results, zasocitinib (Takeda) and envudeucitinib (Alumis), and icotrokinra (Icotyde; Johnson & Johnson), a recently approved oral peptide.
“So, when we have that discussion with our patients, we can let them choose. Do you prefer an injection? Do you

More peanut-allergic toddlers receiving slow up-dosing and a low maintenance dose for peanut oral immunotherapy vs. avoiding peanut tolerated at least 750 mg peanut protein after 3 years, according to study results.
The study, published in The Lancet Regional Health – Europe, noted that this dose equals 3.5 peanuts.
“For routine clinical practice, the principal implication is that this study provides an evidence-based opportunity to offer oral immunotherapy to carefully selected, motivated children with peanut allergy,” Carina Uhl, MD, PhD student at Karolinska Institutet, told Healio.
In the

This month’s Healio Exclusive in Healio Gastroenterology poses a highly topical question.
GLP-1 receptor agonists have revolutionized the treatment of obesity and related conditions, including type 2 diabetes, major adverse cardiovascular events, obstructive sleep apnea, metabolic dysfunction-associated steatotic liver disease, osteoarthritis and polycystic ovarian syndrome.
The benefits of this drug class seem to far outweigh adverse events, which are often gastrointestinal. For some patients, including those with MASLD, gastroesophageal reflux disease or inflammatory bowel disease, there is